Stifel Nicolaus Begins Coverage on Altimmune (NASDAQ:ALT)

Stifel Nicolaus started coverage on shares of Altimmune (NASDAQ:ALT) in a research note released on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $18.00 price target on the stock.

A number of other research firms also recently weighed in on ALT. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. UBS Group assumed coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.71.

Altimmune Stock Performance

Shares of ALT opened at $7.45 on Wednesday. The company has a 50-day simple moving average of $8.08 and a 200-day simple moving average of $7.20. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The firm has a market capitalization of $529.88 million, a P/E ratio of -4.81 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same period last year, the company earned ($0.39) EPS. As a group, equities analysts forecast that Altimmune will post -1.36 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. boosted its stake in shares of Altimmune by 12.9% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after purchasing an additional 2,687 shares during the last quarter. Creative Planning lifted its stake in shares of Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after purchasing an additional 3,132 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares during the period. Larson Financial Group LLC acquired a new position in Altimmune in the third quarter valued at about $31,000. Finally, Arizona State Retirement System raised its position in shares of Altimmune by 34.4% in the 2nd quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock valued at $132,000 after acquiring an additional 5,081 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.